Medicare May Be Stifled in Effective Use of Data

BY ALICIA AUL T
FROM HEALTH AFFAIRS

“The belief that the time is ripe for Medicare to use comparative effectiveness research to reach a new paradigm of paying equally for services that provide equivalent results,” said Dr. Steven D. Pearson, president of the Institute for Clinical and Economic Review, Boston, and Dr. Peter B. Bach of Memorial Sloan-Kettering Cancer Center, New York (Health Affairs 2010;29:1796-804).

The Obama administration is helping create a larger comparative effectiveness enterprise through some $1.1 billion that was set aside as part of the American Recovery and Reinvestment Act of 2009, and 15 experts are to guide investments and coordinate research through the Federal Coordinating Council for Comparative Effectiveness Research.

However, the council’s role is limited. It will not set clinical guidelines, or establish payment rates, or tell Medicare what to cover. The Act further spelled out restrictions on how comparative effectiveness findings could be used by the federal government.

For instance, a superior rating would garner the highest payment. Such a product would have the fewest side effects or offer the most effective treatment when compared with similar treatments.

Next down would be the “comparable” product or service. Payment would be slightly less than that for the superior product, as in the differences between a brand name and a generic pharmaceutical, for example.

The lowest rating would be “insufficient evidence.” The service would be covered and reimbursed at the conventional cost plus a small profit, but the payment level would be reevaluated every 3 years.

The authors said that a 3-year time frame can act as both a carrot and a stick. Having coverage at current Medicare rates is better than not having coverage, so innovation will not be stifled. But limiting that rate to only 3 years gives manufacturers and clinicians greater incentives to conduct comparative effectiveness studies, they said.

The new payment and coverage scheme might end up restricting access to new services, but the authors said they believe the “trade-off would be justifiable” because the services being reimbursed at the lower rate would have the least amount of evidence supporting their use. They also said that using comparative effectiveness data, although threatening to manufacturers, might actually encourage the development of superior products and services. “Paying more for better results is the best way to spur the kind of innovation desired most by patients, clinicians, and payers,” they wrote.

The new approach raises conundrums, they noted. It could be difficult to rate a service if effectiveness differed across patient subgroups. And there is the question of whether previously covered services should be grandfathered in. But overall, said Dr. Pearson and Dr. Bach, the new approach could help spur innovation and reduce costs.

Dr. Pearson and Dr. Bach reported no conflicts of interest.

Levemir® (insulin detemir [IDNA origin] injection)

Levemir® is approved for once-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adults with type 2 diabetes mellitus with inadequate long-term insulin control for hyperglycemia.

CONTAINING: LEVEMIR® is contraindicated in patients hypersensitive to insulin detemir or one of its components.

WARNINGS: Hypoglycemia is the most common adverse effect of insulin therapy, including associated adverse effects of IDNA insulin products that may include allergic reactions, including anaphylaxis. Monitor patients for hypersensitivity reactions. The loss of subcutaneous adipose tissue at the site of injection may increase the frequency of insulin leakage and lead to subcutaneous adipose tissue atrophy. In patients with infections such as cellulitis, abscess, or draining sinus tract, IDNA detemir treatment should be discontinued until the infection is cleared. Infections may lead to an increase in the frequency of insulin leakage. In patients with infections such as cellulitis, abscess, or draining sinus tract, IDNA detemir treatment should be discontinued until the infection is cleared. Infections may lead to an increase in the frequency of insulin leakage.

Levemir products should not be used in patients with a history of multiple allergies, including allergy to IDNA, IDNA-containing products, or any of the components of Levemir, or in patients with a history of eczema, psoriasis, or other inflammatory skin conditions. The use of Levemir may cause a transient rise in blood pressure.

The use of insulin detemir products, including Levemir, may cause respiratory depression and hypersensitivity reactions such as urticaria, urticarial rash, angioedema, and anaphylaxis. Hypersensitivity reactions may occur in patients with allergies to IDNA, and may range from mild to severe. Some hypersensitivity reactions may cause death. Hypersensitivity reactions may also occur in patients with no known history of allergies. Hypersensitivity reactions can occur in patients with no known history of allergies.

Levemir is contraindicated in patients with insulin allergy or known or suspected allergy to IDNA. Levemir is contraindicated in patients with a history of multiple allergies, including allergy to IDNA, IDNA-containing products, or any of the components of Levemir, or in patients with a history of eczema, psoriasis, or other inflammatory skin conditions. The use of Levemir may cause a transient rise in blood pressure.